Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

JAKAFI Product Revenue

JAKAFI Product Revenue % Chg.

JAKAFI Product Revenue Common Size

OPZELURA Product Revenue

OPZELURA Product Revenue % Chg.

OPZELURA Product Revenue Common Size

ICLUSIG Product Revenue

ICLUSIG Product Revenue % Chg.

ICLUSIG Product Revenue Common Size

PEMAZYRE Product Revenue

PEMAZYRE Product Revenue % Chg.

PEMAZYRE Product Revenue Common Size

MINJUVI Product Revenue

MINJUVI Product Revenue % Chg.

MINJUVI Product Revenue Common Size

ZYNYZ Product Revenue

ZYNYZ Product Revenue % Chg.

ZYNYZ Product Revenue Common Size

Total Product Revenue

Total Product Revenue % Chg.

Total Product Revenue Common Size

JAKAVI Royalty Revenue

JAKAVI Royalty Revenue % Chg.

JAKAVI Royalty Revenue Common Size

OLUMIANT Royalty Revenue

OLUMIANT Royalty Revenue % Chg.

OLUMIANT Royalty Revenue Common Size

TABRECTA Royalty Revenue

TABRECTA Royalty Revenue % Chg.

TABRECTA Royalty Revenue Common Size

Other Royalty Revenue

Other Royalty Revenue % Chg.

Other Royalty Revenue Common Size

Total Royalty Revenue

Total Royalty Revenue % Chg.

Total Royalty Revenue Common Size

Milestone and Contract Revenue

Milestone and Contract Revenue % Chg.

Milestone and Contract Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

NIKTIMVO Product Revenue

NIKTIMVO Product Revenue Common Size

Revenue	LTM	Dec '24	Dec '23
JAKAFI Product Revenue	3,037.4	2,792.1	2,593.7
OPZELURA Product Revenue	632.8	508.3	337.9
ICLUSIG Product Revenue	127.2	114.3	111.6
PEMAZYRE Product Revenue	86.5	81.7	83.6
MINJUVI Product Revenue	135.5	119.2	37.1
ZYNYZ Product Revenue	36	3.2	1.3
Total Product Revenue	4,151	3,618.9	3,165.2
JAKAVI Royalty Revenue	441.7	418.8	367.6
OLUMIANT Royalty Revenue	139.9	135.6	136.1
TABRECTA Royalty Revenue	25.8	22.7	17.8
Other Royalty Revenue	4.7	2.2	2
Total Royalty Revenue	612.2	579.3	523.5
Milestone and Contract Revenue	—	43	7
Other Revenue	50	—	—
Total Revenue	4,813.1	4,241.2	3,695.6